Hoffmann-La Roche - Recruiting 6 Months to 18 years. - A Phase II Open-Label, Randomized, Multi-Centre Comparative Study Of Bevacizumab-Based Therapy In Paediatric Patients With Newly Diagnosed Supratentorial, Infratentorial Cerebellar, Or Peduncular High-Grade Glioma.
Genentech - Recruiting 18 years or older. - An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma.
Dr. Negrin University Hospital - Recruiting 18 years to 75 years. - Positron Emission Tomography With Fluoro-misonidazole (PET-FMISO) in High Grade Gliomas: Assessment of Tumor Hypoxia and Effect of Spinal Cord Stimulation.
18F-FMISO; PET without SCS; SCS; PET without/with SCS; Radiotherapy; Temozolomide
St. Jude Children's Research Hospital - Recruiting 2 years to 21 years. - Phase I Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG).
Sidney Kimmel Comprehensive Cancer Center - Recruiting 18 years or older. - A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects With Recurrent High-Grade Glioma Undergoing Standard, Repeated Temozolomide Treatment.
mibefradil dihydrochloride; temozolomide; 3'-deoxy-3'-[18F]fluorothymidine; pharmacological study
Beth Israel Medical Center - Recruiting 18 years to 70 years. - STRONG Trial - Stem Cell Radiotherapy (ScRT) and Temozolomide for Newly Diagnosed High-grade Glioma (HGG): A Prospective, Phase I/II Trial.
National Institutes of Health Clinical Center (CC) - Recruiting N/A to 17 years. - An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-Grade Glioma.
Pediatric Brain Tumor Consortium - Recruiting 16 years to 21 years. - A Phase I Study of Intratumoral/Peritumoral Herpes Simplex Virus-1 Mutant HSV1716 in Patients With Refractory or Recurrent High Grade Gliomas (HGG).
National Cancer Institute (NCI) - Recruiting 3 years to 21 years. - A Randomized Phase II/III Study of Vorinostat (IND# 71976) and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab (IND# 7921) and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas.
Novartis - Recruiting 12 Months to 18 years. - A Phase I/II Study of LDE225 in Pediatric Patients With Recurrent or Refractory Medulloblastoma or Other Tumors Potentially Dependent on the Hedgehog-signaling Pathway and Adult Patients With Recurrent or Refractory Medulloblastoma.
University Ghent - Recruiting 18 years or older. - PET Imaging of High-grade Glioma Using 18F-fluoromethylcholine: a Tool for the Early Detection of Tumour Recurrence After Combined Radiochemotherapy?.
Kentuckiana Cancer Institute - Recruiting 18 years to 75 years. - A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma.